All Updates

All Updates

icon
Filter
Funding
Seismic Therapeutic raises USD 121 million Series B to advance immunology pipeline
AI Drug Discovery
Dec 4, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Dec 4, 2023

Seismic Therapeutic raises USD 121 million Series B to advance immunology pipeline

Funding

  • Massachusetts-based AI-drug discovery company Seismic Therapeutic has secured USD 121 million in a Series B funding round led by Bessemer Venture Partners, with participation from Amgen Ventures, Codon Capital, and other existing investors. This brings the total funds raised by the company to USD 222 million.

  • The funds will be channeled to progress Phase I proof-of-mechanism trials with Seismic’s two leading programs, S-1117 (a pan‑immunoglobulin (Ig) G protease sculpting (Sc) enzyme candidate and S-4321 (a PD-1 agonist:Fc gamma receptor IIb selective dual-cell bidirectional (DcB) antibody candidate) and to support the expansion of the company's IMPACT platform by developing additional methods. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.